Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.98 BRL | -1.49% | -0.33% | +43.64% |
06-13 | Health Care Flat on Mixed Drug Developments - Health Care Roundup | DJ |
06-03 | Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to S&P 1000 | CI |
Evolution of the average Target Price on Sarepta Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Sarepta Therapeutics, Inc.
RBC Capital Markets | |
Mizuho Securities | |
Oppenheimer | |
UBS | |
Morgan Stanley | |
Deutsche Bank Securities | |
Needham & Co. | |
BMO Capital | |
Wedbush | |
Cantor Fitzgerald | |
JPMorgan Chase | |
Goldman Sachs | |
Citigroup | |
Evercore ISI | |
Credit Suisse | |
TD Cowen | |
Baird | |
Berenberg Bank | |
BTIG | |
SVB Securities LLC | |
Guggenheim |
EPS Revisions
- Stock Market
- Equities
- SRPT Stock
- S1RP34 Stock
- Consensus Sarepta Therapeutics, Inc.